AGIO - Agios: Expanded FDA Approval Of Tibsovo Will Lead To Other Opportunities
Agios Pharmaceuticals (AGIO) announced FDA approval for its supplemental new drug application (sNDA) for TIBSOVO to treat newly diagnosed adult acute myeloid leukemia ((AML)) patients who have the IDH1 mutation and are ineligible for intensive chemotherapy. This newly expanded label will help improve sales based on the prior approval of the drug for relapse/refractory AML with IDH1 mutation. The company is in good shape in terms of its pipeline, because it has already received FDA approval for another drug known as IDHIFA.
Expanded Approval Opens Up Market Opportunity
The sNDA approval for TIBSOVO